REGENERON PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

04 апр 2025 09:46:04 Источник NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

03 апр 2025 16:08:52 Источник NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

02 апр 2025 09:45:07 Источник NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

01 апр 2025 14:45:14 Источник NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

31 мар 2025 09:50:37 Источник NetDania Notify

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

28 мар 2025 02:00:14 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 мар 2025 09:46:28 Источник NetDania Notify

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

25 мар 2025 16:05:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

25 мар 2025 14:10:05 Источник NetDania Notify

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

11 мар 2025 21:32:16 Источник Nasdaq GlobeNewswire

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

08 мар 2025 13:00:00 Источник Nasdaq GlobeNewswire

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

28 фев 2025 07:00:02 Источник Nasdaq GlobeNewswire

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

26 фев 2025 07:00:19 Источник Nasdaq GlobeNewswire

Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial

24 фев 2025 15:00:04 Источник Nasdaq GlobeNewswire

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

18 фев 2025 00:59:00 Источник Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

11 фев 2025 16:05:00 Источник Nasdaq GlobeNewswire

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

11 фев 2025 07:00:39 Источник Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

08 фев 2025 17:40:16 Источник Nasdaq GlobeNewswire

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

08 фев 2025 15:55:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

04 фев 2025 09:45:06 Источник NetDania Notify